Immunovia AB
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMVF research report →
About the company
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
- CEO
- Jeff Borcherding
- IPO
- 2019
- Employees
- 13
- HQ
- Lund, NSW, SE
Price Chart
- Market Cap
- $6.11M
- P/E
- -0.70
- P/S
- 72.30
- P/B
- 2.81
- EV/EBITDA
- -0.14
- Div Yield
- 0.00%
- Gross Margin
- -3677.48%
- Op Margin
- -8602.18%
- Net Margin
- -11594.78%
- ROE
- -353.07%
- ROIC
- -168.26%
- Revenue
- $683.28K · -26.61%
- Net Income
- $-145,548,968 · -90.16%
- EPS
- $-0.42 · 54.84%
- Op Income
- $-80,452,000
- FCF YoY
- 19.17%
- 52W High
- $0.15
- 52W Low
- $0.02
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 2.69
- Avg Volume
- 111.2
Get TickerSpark's AI analysis on IMMVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IMMVF coverage
Recent articles, reports, and earnings notes.
No research on IMMVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMMVF report →Similar companies
Peers in the same neighborhood.